XML 28 R13.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stock-Based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2017
Stock-Based Compensation |
Stock-Based Compensation | 7. Stock‑Based Compensation Our Board of Directors and the requisite stockholders previously approved the 2010 Equity Incentive Plan (the 2010 Plan). In October 2013, our Board of Directors approved the 2013 Equity Incentive Plan (the 2013 Plan) and in November 2013 our stockholders approved the 2013 Plan. The 2013 Plan became effective as of December 3, 2013, the date of the Company’s IPO. As of December 2, 2013, we suspended the 2010 Plan and no additional awards may be granted under the 2010 Plan. Any shares of common stock covered by awards granted under the 2010 Plan that terminate after December 2, 2013 by expiration, forfeiture, cancellation or other means without the issuance of such shares will be added to the 2013 Plan reserve. As of December 31, 2017, the total number of shares of common stock available for issuance under the 2013 Plan was 8,526,465. Unless otherwise determined by the Board, beginning January 1, 2014, and continuing until the expiration of the 2013 Plan, the total number of shares of common stock available for issuance under the 2013 Plan will automatically increase annually on January 1 by 4% of the total number of issued and outstanding shares of common stock as of December 31 of the immediate preceding year. On January 1, 2017, the total number of shares of common stock available for issuance under the 2013 Plan was automatically increased by 1,862,719 shares, which number is included in the number of shares available for issuance above. As of December 31, 2017 a total of 4,945,350 options have been issued under the 2013 Plan. In November 2013, our Board of Directors and stockholders approved the 2013 Employee Stock Purchase Plan (ESPP), which became effective as of December 5, 2013. Under the ESPP our employees may elect to have between 1-15% of their compensation withheld to purchase Company stock at a discount. The ESPP had an initial two-year term that includes four six-month purchase periods and employee withholding amounts may be used to purchase Company stock during each six-month purchase period. The initial two-year term ended in December 2015 and pursuant to the provisions of the ESPP, the second two-year term began automatically upon the end of the initial term. The total number of shares that can be purchased with the withholding amounts are based on the lower of 85% of the Company’s stock price at the initial offering date or, 85% of the Company’s stock price at each purchase date. We have reserved a total of 581,286 shares of common stock for issuance under the ESPP. Unless otherwise determined by our Board, beginning on January 1, 2014, and continuing until the expiration of the ESPP, the total number shares of common stock available for issuance under the ESPP will automatically increase annually on January 1 by the lesser of (i) 1% of the total number of issued and outstanding shares of common stock as of December 31 of the immediately preceding year, or (ii) 621,814 shares of common stock. On January 1, 2014, the total number of shares of common stock available for issuance under the ESPP was automatically increased by 313,545 shares, which number is included in the number of shares reserved for issuance above. Pursuant to approval by our board, there was no increase in the number of authorized shares in the ESPP in 2017, 2016 or 2015. As of December 31, 2017 and 2016, we have issued a total of 292,393 and 221,486 shares of common stock, respectively, under the ESPP. Information with respect to stock options outstanding is as follows:
|  | December 31, |
|  | 2017 |  | 2016 |  | 2015 |
Exercisable options |  |  | 2,558,941 |  |  | 1,743,765 |  |  | 1,600,351 |
Weighted average exercise price per share of exercisable options |  | $ | 11.06 |  | $ | 8.87 |  | $ | 3.99 |
Weighted average grant date fair value per share of options granted during the year |  | $ | 16.92 |  | $ | 10.30 |  | $ | 10.66 |
Options available for future grants |  |  | 3,394,651 |  |  | 2,943,216 |  |  | 2,917,182 |
Weighted average remaining contractual life |  |  | 6.58 |  |  | 7.82 |  |  | 6.98 |
The following table summarizes stock option activity for the years ended December 31, 2017 and 2016:
|  |  |  |  |  |  | Weighted- |  |  |  |
|  |  |  | Weighted- |  | Average |  |  |  |
|  |  |  | Average |  | Remaining |  |  |  |
|  |  |  | Exercise |  | Contractual |  | Aggregate |
|  | Number of |  | Price |  | Term |  | Intrinsic Value |
|  | Shares |  | (Per Share)(1) |  | (in years) |  | (in thousands)(2) |
Balances at December 31, 2015 |  | 3,370,901 |  | $ | 8.50 |  | 6.98 |  |  |  |
Options granted |  | 1,429,500 |  |  | 15.08 |  |  |  |  |  |
Options forfeited |  | (54,503) |  |  | 12.21 |  |  |  |  |  |
Options expired |  | (1,031) |  |  | 15.69 |  |  |  |  |  |
Options exercised(3) |  | (699,066) |  |  | 1.66 |  |  |  |  |  |
Balances at December 31, 2016 |  | 4,045,801 |  |  | 11.95 |  | 7.82 |  | $ | 58,131 |
Options granted |  | 1,511,100 |  |  | 22.61 |  |  |  |  |  |
Options forfeited |  | (96,856) |  |  |  |  |  |  |  |  |
Options expired |  | (3,000) |  |  |  |  |  |  |  |  |
Options exercised(3) |  | (363,603) |  |  |  |  |  |  |  |  |
Balances at December 31, 2017 |  | 5,093,442 |  | $ | 15.32 |  |  |  | $ |  |
As of December 31, 2017 |  |  |  |  |  |  |  |  |  |  |
Options vested and expected to vest |  | 5,093,442 |  | $ | 15.32 |  | 7.62 |  | $ | 35,495 |
Exercisable |  | 2,558,941 |  | $ | 11.06 |  | 6.58 |  | $ | 28,017 |
| (1) |  | The weighted average exercise price per share is determined using exercise price per share for stock options.
| (2) |  | The aggregate intrinsic value is calculated as the difference between the exercise price of the option and the fair value of our common stock for in‑ the‑money options at December 31, 2017 and 2016.
| (3) |  | The total intrinsic value of stock options exercised was $5.7 million, $11.2 million and $5.4 million for the years ended December 31, 2017, 2016 and 2015 respectively.
The stock options outstanding and exercisable by exercise price at December 31, 2017 are as follows:
Stock Options Outstanding |  | Stock Options Exercisable |
|  |  |  | Weighted- |  |  |  |  |  |  |  |  |
|  |  |  | Average |  |  |  |  |  |  |  |  |
|  |  |  | Remaining |  | Weighted- |  |  |  | Weighted- |
Range of |  |  |  | Contractual |  | Average |  |  |  | Average |
Exercise |  | Number of |  | Term |  | Exercise Price |  | Number of |  | Exercise Price |
Prices |  | Shares |  | (in years) |  | Per Share |  | Shares |  | Per Share |
$0.59 – $4.25 |  | 622,046 |  | 4.82 |  | $ | 3.17 |  | 622,046 |  | $ | 3.17 |
$9.26 – $13.89 |  | 1,781,232 |  | 7.26 |  | $ | 11.87 |  | 1,205,142 |  | $ | 11.64 |
$14.10 – $21.15 |  | 968,314 |  | 7.40 |  | $ | 15.8 |  | 634,199 |  | $ | 15.68 |
$21.28 – $26.76 |  | 1,721,850 |  | 9.13 |  | $ | 23.0 |  | 97,554 |  | $ | 24.13 |
|  | 5,093,442 |  | 7.62 |  | $ | 15.32 |  | 2,558,941 |  | $ | 11.06 |
We estimated the fair value of employee and non‑employee awards using the Black‑Scholes valuation model. The fair value of employee stock options is being amortized on a straight‑line basis over the requisite service period of the awards. Management estimates the probability of non‑employee awards being vested based upon an evaluation of the non‑employee achieving their specific performance goals. Options granted after our Initial Public Offering, are issued at the fair market value of our stock at the date the grant is approved by our board of directors. The fair value of employee stock options was estimated using the following weighted average assumptions for the years ended December 31, 2017, 2016 and 2015:
|  | Options |
|  | 2017 |  | 2016 |  | 2015 |
Common stock fair value per share |  | $ | 19.61 - 25.67 |  | $ | 11.50 - 26.76 |  | $ | 11.82 - 22.35 |
Expected volatility |  |  | 77.42% - 96.73% |  |  | 75.77% - 90.83% |  |  | 69.17% - 86.46% |
Risk-free interest rate |  |  | .96% - 2.37% |  |  | 1.03% - 2.18% |  |  | 1.44% - 1.84% |
Expected dividend yield |  |  | — |  |  | — |  |  | — |
Expected term (in years) |  |  | 5.23 - 6.08 |  |  | 5.23 - 6.08 |  |  | 5.23 - 6.08 |
|  | ESPP
|  | 2017 |  | 2016 |  | 2015
Expected term (years) |  | 0.5 - 2.0 |  | 0.5 - 2.0 |  | 0.5 - 2.0
Expected volatility |  | 67.8% - 79.8% |  | 67.8% - 79.8% |  | 67.8% - 82.9%
Risk-free interest rate |  | .47% - 1.8% |  | .47% - .93% |  | .07% - .93%
Expected dividend yield |  | — |  | — |  | —
Total employee, director and non‑employee stock‑based compensation expense recognized was as follows:
|  | Year Ended |
|  | December 31, |
(In thousands) |  | 2017 |  | 2016 |  | 2015 |
General and administrative |  | $ | 5,617 |  | $ | 3,592 |  | $ | 2,218 |
Research and development |  |  | 8,034 |  |  | 4,256 |  |  | 2,650 |
|  | $ | 13,651 |  | $ | 7,848 |  | $ | 4,869 |
The expected term of stock options represents the average period the stock options are expected to remain outstanding. The expected stock price volatility for our stock options for the years ended December 31, 2017, 2016 and 2015 was determined by examining the historical volatilities for industry peers and adjusting for differences in our life cycle and financing leverage. Industry peers consist of several public companies in the biopharmaceutical industry. We determined the average expected life of stock options based on the simplified method because our common stock has not been publicly traded for an extended period and we do not have a track record of our stock being traded on the public markets for sufficient time to establish the volatility of our stock. The risk‑free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of our stock options. The expected dividend assumption is based on our history and expectation of dividend payouts. As of December 31, 2017 and 2016, the unamortized compensation expense related to unvested stock options was $30.7 million and $18.1 million, respectively. The remaining unamortized compensation expense will be recognized over the next 2.76 years. At December 31, 2017 and 2016, the unamortized compensation expense was $1.1 million and $481,000 respectively under our ESPP. The remaining unamortized expense will be recognized over the next 23.3 months.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration